These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
A New Native Mass Spectrometry Platform Identifies Inhibitors of the HSP90 – HOP Protein-Protein Interaction
preprintsubmitted on 10.06.2020, 16:37 and posted on 11.06.2020, 13:27 by Clinton Veale, Mateos-Jimenez, Maria, Michaelone Vaaltyn, Ronel Müller, Matodzi Makhubu, Mahama Alhassan, Beatriz G. de la Torre, Fernando Albericio, C. Logan Mackay, Adrienne L. Edkins, David Clarke
This communication discusses for the first time, the use of mass spectrometry as a platform for screening for PPI inhibitors, without protein tethering or labeling. Furthermore, in the context of cancer drug discovery, this study demonstrates the ligandability and therefore the potential druggability of HOP, whose PPI with HSP90 has been routinely discussed as a difficult to drug target of substantial potential.
Underpinning UK Biomolecular Research with Next-Generation High Resolution Mass Spectrometry at the University of Edinburgh
Biotechnology and Biological Sciences Research CouncilFind out more...